Senseonics (NASDAQ:SENS – Free Report) had its target price raised by Mizuho from $18.00 to $20.00 in a research report released on Tuesday, Marketbeat reports. The firm currently has an outperform rating on the stock.
A number of other research analysts also recently weighed in on SENS. Barclays raised their price objective on Senseonics from $10.00 to $11.00 and gave the company an “equal weight” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Senseonics in a research report on Tuesday. Stifel Nicolaus reaffirmed a “hold” rating and set a $10.00 target price (up from $9.00) on shares of Senseonics in a research report on Tuesday. Weiss Ratings upgraded Senseonics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Finally, TD Cowen lifted their price target on shares of Senseonics from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Senseonics currently has a consensus rating of “Hold” and a consensus price target of $14.40.
Check Out Our Latest Stock Report on SENS
Senseonics Price Performance
Senseonics stock opened at $10.04 on Tuesday. Senseonics has a one year low of $4.79 and a one year high of $13.98. The company’s fifty day moving average price is $9.16 and its two-hundred day moving average price is $7.31. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.92 and a quick ratio of 6.40.
Senseonics (NASDAQ:SENS – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). The company had revenue of $19.56 million during the quarter. Senseonics had a negative return on equity of 186.11% and a negative net margin of 204.01%. As a group, analysts anticipate that Senseonics will post -2.30 earnings per share for the current year.
Insider Buying and Selling at Senseonics
In other Senseonics news, Director Douglas Roeder bought 13,953 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average price of $8.98 per share, for a total transaction of $125,297.94. Following the purchase, the director directly owned 171,191 shares in the company, valued at $1,537,295.18. This trade represents a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.70% of the company’s stock.
Institutional Trading of Senseonics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SENS. State of Wyoming increased its position in Senseonics by 27.2% in the 3rd quarter. State of Wyoming now owns 14,940 shares of the company’s stock worth $152,000 after buying an additional 3,199 shares during the period. Integrated Wealth Concepts LLC bought a new stake in shares of Senseonics in the second quarter valued at approximately $36,000. Kestra Advisory Services LLC bought a new stake in shares of Senseonics in the first quarter valued at approximately $68,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Senseonics in the second quarter worth $65,000. Finally, StoneX Group Inc. acquired a new stake in shares of Senseonics in the third quarter worth $128,000. Institutional investors and hedge funds own 12.36% of the company’s stock.
Key Stories Impacting Senseonics
Here are a few of the latest stories about SENS:
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $14 price target. It also raised its FY2026 estimate and improved its forecasts for FY2028–FY2030, suggesting a more favorable longer-term earnings trajectory. HC Wainwright rating reaffirmed
- Positive Sentiment: Other analyst headlines cite strong price-appreciation outlooks from Mizuho and Barclays, and a TD Cowen price-target increase. Mizuho forecast Barclays forecast TD Cowen target
- Neutral Sentiment: Analyst opinions are not uniformly bullish: Stifel Nicolaus assigned a Hold rating, while Raymond James upgraded SENS to Market Perform. Stifel rating Raymond James rating
Senseonics Company Profile
Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.
Read More
- Five stocks we like better than Senseonics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.
